Di Zhao

Di Zhao

Auto-generated profile, based on publicly available information

Di Zhao

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Genes & Development
Verified
Journal Article
Open access
PDF file
GWGuocan Wang
Guocan Wang
DZDi Zhao
Di Zhao
DSDenise J. Spring
Denise J. Spring
RDRonald A. Depinho
Ronald A. Depinho
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is driven by the lack of therapeutic regimens capable of generating durable responses in the setting of extreme tumor heterogeneity on the genetic and cell biological levels. Here, we review available prostate cancer model systems, the prostate cancer genome atlas, cellular and functional heterogeneity in the tumor microenvironment, tumor-intrinsic and tumor-extrinsic mechanisms underlying therapeutic resistance, and technological advances focused on disease detection and management. These advances, along with an improved understanding of the adaptive responses to conventional cancer therapies, anti-androgen therapy, and immunotherapy, are catalyzing development of more effective therapeutic strategies for advanced disease. In particular, knowledge of the heterotypic interactions between and coevolution of cancer and host cells in the tumor microenvironment has illuminated novel therapeutic combinations with a strong potential for more durable therapeutic responses and eventual cures for advanced disease. Improved disease management will also benefit from artificial intelligence-based expert decision support systems for proper standard of care, prognostic determinant biomarkers to minimize overtreatment of localized disease, and new standards of care accelerated by next-generation adaptive clinical trials.

1 April 2019 in Cancer Cell
Verified
Journal Article
Closed access
WLWenting Liao
Wenting Liao
MOMichael J. Overman
Michael J. Overman
ABAdam T. Boutin
Adam T. Boutin
XSXiaoying Shang
Xiaoying Shang
DZDi Zhao
Di Zhao
RDRonald A. Depinho
Ronald A. Depinho

1 June 2011 in Molecular Cell
Verified
Journal Article
Closed access
LLLei Lv
Lei Lv
DLDong Li
Dong Li
DZDi Zhao
Di Zhao
RLRuiting Lin
Ruiting Lin
YCYajing Chu
Yajing Chu
QLQun-Ying Lei
Qun-Ying Lei

1 January 2016 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
GWGuocan Wang
Guocan Wang
XLXin Lu
Xin Lu
PDPrasenjit Dey
Prasenjit Dey
PDPingna Deng
Pingna Deng
CWChia Chin Wu
Chia Chin Wu
RDRonald A. Depinho
Ronald A. Depinho
The signaling mechanisms between prostate cancer cells and infiltrating immune cells may illuminate novel therapeutic approaches. Here, utilizing a prostate adenocarcinoma model driven by loss of Pten and Smad4, we identify polymorphonuclear myeloid-derived suppressor cells (MDSC) as the major infiltrating immune cell type, and depletion of MDSCs blocks progression. Employing a novel dual reporter prostate cancer model, epithelial and stromal transcriptomic profiling identified CXCL5 as a cancer-secreted chemokine to attract CXCR2-expressing MDSCs, and, correspondingly, pharmacologic inhibition of CXCR2 impeded tumor progression. Integrated analyses identified hyperactivated Hippo–YAP signaling in driving CXCL5 upregulation in cancer cells through the YAP–TEAD complex and promoting MDSC recruitment. Clinicopathologic studies reveal upregulation and activation of YAP1 in a subset of human prostate tumors, and the YAP1 signature is enriched in primary prostate tumor samples with stronger expression of MDSC-relevant genes. Together, YAP-driven MDSC recruitment via heterotypic CXCL5–CXCR2 signaling reveals an effective therapeutic strategy for advanced prostate cancer. Significance: We demonstrate a critical role of MDSCs in prostate tumor progression and discover a cancer cell nonautonomous function of the Hippo–YAP pathway in regulation of CXCL5, a ligand for CXCR2-expressing MDSCs. Pharmacologic elimination of MDSCs or blocking the heterotypic CXCL5–CXCR2 signaling circuit elicits robust antitumor responses and prolongs survival. Cancer Discov; 6(1); 80–95. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 1

1 November 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CLChen-Ying Liu
Chen-Ying Liu
ZZZheng-Yu Zha
Zheng-Yu Zha
XZXin Zhou
Xin Zhou
HZHeng Zhang
Heng Zhang
WHWei Huang
Wei Huang
KGKun-Liang Guan
Kun-Liang Guan
The TAZ transcription co-activator promotes cell proliferation and epithelial-mesenchymal transition. TAZ is inhibited by the Hippo tumor suppressor pathway, which promotes TAZ cytoplasmic localization by phosphorylation. We report here that TAZ protein stability is controlled by a phosphodegron recognized by the F-box protein β-TrCP and ubiquitylated by the SCF/CRL1β-TrCP E3 ligase. The interaction between TAZ and β-TrCP is regulated by the Hippo pathway. Phosphorylation of a phosphodegron in TAZ by LATS primes it for further phosphorylation by CK1ϵ and subsequent binding by β-TrCP. Therefore, the Hippo pathway negatively regulates TAZ function by both limiting its nuclear accumulation and promoting its degradation. The phosphodegron-mediated TAZ degradation plays an important role in negatively regulating TAZ biological functions.

1 June 2019 in Cancer Cell
Verified
Journal Article
Closed access
PCPeiwen Chen
Peiwen Chen
DZDi Zhao
Di Zhao
JLJun Li
Jun Li
XLXin Liang
Xin Liang
JLJiexi Li
Jiexi Li
RDRonald A. Depinho
Ronald A. Depinho